SDSebastian Diecke

Sebastian Diecke

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Sebastian Diecke has a total of 357 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Proteomics identify disease-associated variants in patients with rare diseases undiagnosed after genome sequencing

    by Julia Carrasco-Zanini, Jorge Andrade, Maik Pietzner, Athanasios Kousathanas, Julius O. B. Jacobsen, Jenny Lord, Narasimha Telugu, Sebastian Diecke, Michael Mülleder, Dominik Bierbaum, et al.

    Despite the introduction of genome sequencing (GS) for rare disease diagnostics, a genetic cause is not identified in most patients. Here, we explored the potential of proteomics to improve the diagnostic yield in 424 patients with rare diseases from the 100,000 Genomes Project (100kGP) without a genetic diagnosis. Serum proteomic profiling was performed using the Olink Explore 1536 assay ( N = 1463 proteins). For 13 patients without genetic diagnoses, detection of lower serum protein “outliers” ( z -score < −2) led to confirmed genetic diagnoses by resolving variants of uncertain significance or prioritizing genes for targeted GS reanalysis. For 23 additional patients without genetic diagnoses (64% of findings), we identified candidate gene-disease links and variants through convergent evidence from lower protein outliers and variants ranked through the variant prioritization tool Exomiser. For example, we identified a candidate heterozygous missense variant [Genome Aggregation Database (gnomAD) minor allele frequency = 0.006%] in tyrosine kinase with immunoglobulin-like and epidermal growth factor homology domains 1 ( TIE1 ) that was only present in a patient with lower TIE1 serum abundance ( z -score = −5.12) and their father, both of whom were affected by the same monogenic cardiac disorder, but in no other individuals from the 100kGP. Missense (52.5%) and splice region (27.5%) variants accounted for most diagnostic or candidate variants prioritized. This proof-of-principle study demonstrated that serum proteomics can support rare disease diagnosis and identify disease-causing genes in patients undiagnosed after GS, although successful implementation will likely depend on tissue specificity of protein expression, detectability in blood, proteomic platform coverage, and sensitivity.

  • Open Access

    Innervated human cardiac muscle model reveals sympathetic drivers of KCNH2-associated arrhythmias

    by Lennart Valentin Schneider, Michael Gani Setya, Guobin Bao, Daniel Härtter, Aditi Methi, Dennis Krüger, Marie Kristin Schreiber, Ole Jensen, Elisavet Kanari, Kea Aline Schmoll, et al.

    Cardiac autonomic neurons regulate contractility. Autonomic nervous system dysregulation can cause sympathetic overdrive, leading to heart failure, and fatal arrhythmias. Here, we introduce innervated engineered human myocardium (iEHM), a model of neuro-cardiac junctions, constructed by fusing sympathetic neuronal organoids (SNO) and engineered human myocardium (EHM). Projections of sympathetic neurons formed presynaptic terminals in close proximity to cardiomyocytes and to the extensive vascular network co-developing in iEHM. Contractile responses to optogenetic stimulation of the accordingly engineered neuronal component demonstrated functional neuro-cardiac junctions. Modeling long-QT 2 in iEHM revealed sympathetic neuron hyperactivity and after depolarizations, underscoring a central role for sympathetic drive in KCNH2 -associated arrhythmias. β-adrenoreceptor blockade was insufficient to rescue the pro-arrhythmic phenotype, while mexiletine targeting both neurons and cardiomyocytes, proved to be more effective. Collectively, our data establishes iEHM as a New Approach Methodology that provides a human-relevant, physiologically integrated model for mechanistic investigations and pharmacological testing.

  • Open Access

    CRISPR-MiX: A pooled single-stranded donor strategy to enhance HDR efficiency in human iPSCs

    by Rachel Baum, Narasimha Telugu, Arne A.N. Bruyneel, Maryam Kay, Pooja Nair, Isaac Perea-Gil, Vittavat Termglinchan, Nike Bharucha, Edina Lee, Mark Mercola, et al.


  • Open Access

    StemCNV-check : a pipeline for human pluripotent stem cell (hPSC) genomic integrity control using SNP array data and copy number variant scoring

    by Nicolai von Kügelgen, Valeria Fernandez Vallone, Katarzyna A. Ludwik, Mariia Babaeva, Sebastian Diecke, Dieter Beule, Harald Stachelscheid

    Human pluripotent stem cells (hPSCs) and other continuously cultured cell lines are prone to acquiring mutations and genomic aberrations over time, even when derived from well-characterized cell banks. To ensure experimental reproducibility and maintain cell line integrity, routine monitoring for genomic abnormalities is essential. Single nucleotide polymorphism (SNP) arrays represent a cost-effective and widely accessible method for detecting copy number variations (CNVs) with genome-wide resolution, making them particularly suitable for quality control (QC) in cell culture systems. Despite the established utility of SNP arrays for CNV detection, there remains a lack of comprehensive, user-friendly software solutions that support end-to-end analysis tailored to hPSC line quality assessment. Existing tools are either limited to discrete analysis steps requiring specialized bioinformatics expertise or are proprietary solutions that do not adequately address the specific needs of cell line monitoring. To bridge this gap, we developed an accessible and integrated analysis pipeline for SNP array-based QC of hPSC lines. The pipeline facilitates all stages of analysis—from raw data processing to the generation of interpretable reports—and includes specialized features such as sample-to-reference comparison, a CNV scoring system according to CNV biological impact, single nucleotide variation (SNV) evaluation and identity verification via SNP genotyping profiles, all tailored to hPSC. We benchmarked the pipeline against established methodologies and implemented strategies to enhance CNV detection reliability through expert-guided improvement process.


  • Open Access

    Interaction of sortilin with apolipoprotein E3 enables neurons to use long-chain fatty acids as alternative metabolic fuel

    by Anna K. Greda, Jemila P. Gomes, Vanessa Schmidt-Krueger, Ewa Zurawska-Plaksej, Raphaela Fritsche-Guenther, Ina-Maria Rudolph, Narasimha S. Telugu, Cagla Cömert, Jennifer Kirwan, Séverine Kunz, et al.

    Sortilin (SORT1) is a lipoprotein receptor that shows genome-wide association with hypercholesterolaemia, explained by its ability to control hepatic output of lipoproteins. Although SORT1 also shows genome-wide association with Alzheimer disease and frontotemporal lobe dementia, the most prevalent forms of age-related dementias, sortilin’s contribution to human brain lipid metabolism and health remains unclear. Here we show that sortilin mediates neuronal uptake of polyunsaturated fatty acids carried by apolipoprotein E (apoE). Using humanized mouse strains and induced pluripotent stem cell-based cell models of brain lipid homeostasis, we demonstrate that internalized lipids are converted into ligands for peroxisome proliferator-activated receptor alpha inducing transcription profiles that enable neurons to use long-chain fatty acids as metabolic fuel when glucose is limited. This pathway works with apoE3 but cannot operate with the Alzheimer disease risk factor apoE4, which disrupts sortilin’s endocytic activity. Our data indicate a role for the lipoprotein receptor sortilin in metabolic fuel choice in neurons, which may be crucial when glucose supply is limited, such as in the ageing brain.


  • Open Access

    Familial Alzheimer's disease mutation identifies novel role of SORLA in release of neurotrophic exosomes

    by Kristian Juul‐Madsen, Ina‐Maria Rudolph, Jemila P. Gomes, Katrina Meyer, Peter L. Ovesen, Malgorzata Gorniak‐Walas, Marianna Kokoli, Narasimha S. Telugu, Malthe von Tangen Sivertsen, Fabia Febbraro, et al.

    INTRODUCTION: Mutations in SORL1 , encoding the sorting receptor Sortilin‐related receptor with A‐type repeats (SORLA), are found in individuals with Alzheimer's disease (AD). We studied SORLA N1358S , carrying a mutation in its ligand binding domain, to learn more about receptor functions relevant for human brain health. METHODS: We investigated consequences of SORLA N1358S expression in induced pluripotent stem cell (iPSC)‐derived human neurons and microglia, using unbiased proteome screens and functional cell assays. RESULTS: We identified alterations in the SORLA N1358S interactome linked to biogenesis of exosomes. Consequently, the mutant receptor failed to promote release and neurotrophic qualities of exosomes, a defect attributed to altered exosomal content of microRNAs controlling neuronal maturation. DISCUSSION: We identified a role for SORLA in controlling quantity and neurotrophic quality of exosomes secreted by cells, suggesting impaired cellular cross talk through exosomes as a pathological trait contributing to AD pathology in carriers of SORL1 variants. Highlights: Familial Alzheimer's disease mutation in SORL1 changes interactome of mutant Sortilin‐related receptor with A‐type repeats (SORLA). Mutant SORLA impairs release of exosomes from neurons and microglia. Mutant exosomes lack neurotrophic qualities. Defect linked to alterations in microRNA content.


  • Top Cited Papers
    Open Access

    Engineered heart muscle allografts for heart repair in primates and humans

    by Ahmad-Fawad Jebran, Tim Seidler, Malte Tiburcy, Maria Daskalaki, Ingo Kutschka, Buntaro Fujita, Stephan Ensminger, Felix Bremmer, Amir Moussavi, Huaxiao Yang, et al.

    Cardiomyocytes can be implanted to remuscularize the failing heart1–7. Challenges include sufficient cardiomyocyte retention for a sustainable therapeutic impact without intolerable side effects, such as arrhythmia and tumour growth. We investigated the hypothesis that epicardial engineered heart muscle (EHM) allografts from induced pluripotent stem cell-derived cardiomyocytes and stromal cells structurally and functionally remuscularize the chronically failing heart without limiting side effects in rhesus macaques. After confirmation of in vitro and in vivo (nude rat model) equivalence of the newly developed rhesus macaque EHM model with a previously established Good Manufacturing Practice-compatible human EHM formulation8, long-term retention (up to 6 months) and dose-dependent enhancement of the target heart wall by EHM grafts constructed from 40 to 200 million cardiomyocytes/stromal cells were demonstrated in macaques with and without myocardial infarction-induced heart failure. In the heart failure model, evidence for EHM allograft-enhanced target heart wall contractility and ejection fraction, which are measures for local and global heart support, was obtained. Histopathological and gadolinium-based perfusion magnetic resonance imaging analyses confirmed cell retention and functional vascularization. Arrhythmia and tumour growth were not observed. The obtained feasibility, safety and efficacy data provided the pivotal underpinnings for the approval of a first-in-human clinical trial on tissue-engineered heart repair. Our clinical data confirmed remuscularization by EHM implantation in a patient with advanced heart failure.


  • Open Access

    Reassessment of marker genes in human induced pluripotent stem cells for enhanced quality control

    by Jochen Dobner, Sebastian Diecke, Jean Krutmann, Alessandro Prigione, Andrea Rossi

    Human induced pluripotent stem cells (iPSCs) have great potential in research, but pluripotency testing faces challenges due to non-standardized methods and ambiguous markers. Here, we use long-read nanopore transcriptome sequencing to discover 172 genes linked to cell states not covered by current guidelines. We validate 12 genes by qPCR as unique markers for specific cell fates: pluripotency (CNMD, NANOG, SPP1), endoderm (CER1, EOMES, GATA6), mesoderm (APLNR, HAND1, HOXB7), and ectoderm (HES5, PAMR1, PAX6). Using these genes, we develop a machine learning-based scoring system, “hiPSCore”, trained on 15 iPSC lines and validated on 10 more. hiPSCore accurately classifies pluripotent and differentiated cells and predicts their potential to become specialized 2D cells and 3D organoids. Our re-evaluation of cell fate marker genes identifies key targets for future studies on cell fate assessment. hiPSCore improves iPSC testing by reducing time, subjectivity, and resource use, thus enhancing iPSC quality for scientific and medical applications.


  • Open Access

    Mutant huntingtin impairs neurodevelopment in human brain organoids through CHCHD2-mediated neurometabolic failure

    by Pawel Lisowski, Selene Lickfett, Agnieszka Rybak-Wolf, Carmen Menacho, Stephanie Le, Tancredi Massimo Pentimalli, Sofia Notopoulou, Werner Dykstra, Daniel Oehler, Sandra López-Calcerrada, et al.

    Expansion of the glutamine tract (poly-Q) in the protein huntingtin (HTT) causes the neurodegenerative disorder Huntington’s disease (HD). Emerging evidence suggests that mutant HTT (mHTT) disrupts brain development. To gain mechanistic insights into the neurodevelopmental impact of human mHTT, we engineered male induced pluripotent stem cells to introduce a biallelic or monoallelic mutant 70Q expansion or to remove the poly-Q tract of HTT. The introduction of a 70Q mutation caused aberrant development of cerebral organoids with loss of neural progenitor organization. The early neurodevelopmental signature of mHTT highlighted the dysregulation of the protein coiled-coil-helix-coiled-coil-helix domain containing 2 (CHCHD2), a transcription factor involved in mitochondrial integrated stress response. CHCHD2 repression was associated with abnormal mitochondrial morpho-dynamics that was reverted upon overexpression of CHCHD2. Removing the poly-Q tract from HTT normalized CHCHD2 levels and corrected key mitochondrial defects. Hence, mHTT-mediated disruption of human neurodevelopment is paralleled by aberrant neurometabolic programming mediated by dysregulation of CHCHD2, which could then serve as an early interventional target for HD.


  • Open Access

    A Standardized Nomenclature Design for Systematic Referencing and Identification of Animal Cellular Material

    by Lisa Schrade, Nancy Mah, Anita Bandrowski, Ying Chen, Johannes Dewender, Sebastian Diecke, Christian Hiepen, Madeline A. Lancaster, Tomas Marques-Bonet, Sira Martinez, et al.

    The documentation, preservation and rescue of biological diversity increasingly uses living biological samples. Persistent associations between species, biosamples, such as tissues and cell lines, and the accompanying data are indispensable for using, exchanging and benefiting from these valuable materials. Explicit authentication of such biosamples by assigning unique and robust identifiers is therefore required to allow for unambiguous referencing, avoid identification conflicts and maintain reproducibility in research. A predefined nomenclature based on uniform rules would facilitate this process. However, such a nomenclature is currently lacking for animal biological material. We here present a first, standardized, human-readable nomenclature design, which is sufficient to generate unique and stable identifying names for animal cellular material with a focus on wildlife species. A species-specific human- and machine-readable syntax is included in the proposed standard naming scheme, allowing for the traceability of donated material and cultured cells, as well as data FAIRification. Only when it is consistently applied in the public domain, as publications and inter-institutional samples and data are exchanged, distributed and stored centrally, can the risks of misidentification and loss of traceability be mitigated. This innovative globally applicable identification system provides a standard for a sustainable structure for the long-term storage of animal bio-samples in cryobanks and hence facilitates current as well as future species conservation and biomedical research.